Molecular Cancer Therapeutics CTRC-AACR San Antonio Breast Cancer Symposium Bridging the Lab and the Clinic in Cancer Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yacoub, A.
Right arrow Articles by Dent, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yacoub, A.
Right arrow Articles by Dent, P.
Vol. 2, 623-632, July 2003     Molecular Cancer Therapeutics
© 2003 American Association for Cancer Research

MDA-7 (Interleukin-24) Inhibits the Proliferation of Renal Carcinoma Cells and Interacts with Free Radicals to Promote Cell Death and Loss of Reproductive Capacity1

Adly Yacoub, Clint Mitchell, Jessica Brannon, Elizabeth Rosenberg, Liang Qiao, Robert McKinstry, W. Marston Linehan, Zao-shong Su, Devanand Sarkar, Irina V. Lebedeva, Kristoffer Valerie, Rahul V. Gopalkrishnan, Steven Grant, Paul B. Fisher and Paul Dent2

Departments of Radiation Oncology [A. Y., C. M., J. B., E. R., L. Q., R. M., K. V., P. D.] and Hematology/Oncology [S. G.], Virginia Commonwealth University, Richmond, Virginia 23298; National Cancer Institute, Urologic Oncology Branch, Bethesda, Maryland 20852 [W. M. L.]; and Departments of Pathology [Z-s. S., D. S., I. V. L., R. V. G., P. B. F.], Neurosurgery [P. B. F.], and Urology [P. B. F.], Columbia University, New York, New York 10032

2 To whom requests for reprints should be addressed, at Department of Radiation Oncology, Medical College of Virginia, Virginia Commonwealth University, 401 College Street, Richmond, VA 23298-0058. Phone: (804) 628-0861; Fax: (804) 828-6042; E-mail: pdent{at}hsc.vcu.edu

The median survival of metastatic renal cell carcinoma (RCC) is 12 months, and the majority of treatment options are palliative. MDA-7 (interleukin-24), when expressed via a recombinant replication defective adenovirus, Ad.mda-7, has profound antiproliferative and cytotoxic effects in a wide variety of tumor cells but not in nontransformed cells. The studies in this study examined the impact of MDA-7 on RCC proliferation and survival. RCC lines (A498 and UOK121N), but not primary renal epithelial cells, were resistant to adenoviral infection that correlated with a lack of coxsackievirus and adenovirus receptor expression. Additional studies were performed using purified preparations of bacterially synthesized glutathione S-transferase (GST)-MDA-7 protein. GST-MDA-7, but not GST, caused a dose-dependent inhibition of RCC proliferation but not of primary renal epithelial cells. Clinically achievable concentrations of the novel therapeutic agent arsenic trioxide (0.5–1 µM) were found to have little effect on RCC growth. However, the combination of GST-MDA-7 and arsenic trioxide resulted in a greater than additive reduction in cell growth that correlated with a large increase in tumor cell death. The free radical scavenger N-acetyl cysteine abolished the potentiating effect of arsenic trioxide. Although pro-caspase 3, poly(ADP-ribose) polymerase, and Bcl-XL levels, as well as nucleosomal DNA integrity, were reduced by combined treatment, cell killing was predominantly nonapoptotic. Combined treatment of RCC lines with GST-MDA-7 and arsenic trioxide also resulted in a substantial reduction in clonogenic survival compared with either treatment individually. Collectively, these findings demonstrate that MDA-7 protein, in combination with agents that generate free radicals, may have potential in the treatment of RCC.




This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
A. Yacoub, M. A. Park, P. Gupta, M. Rahmani, G. Zhang, H. Hamed, D. Hanna, D. Sarkar, I. V. Lebedeva, L. Emdad, et al.
Caspase-, cathepsin-, and PERK-dependent regulation of MDA-7/IL-24-induced cell killing in primary human glioma cells
Mol. Cancer Ther., February 1, 2008; 7(2): 297 - 313.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
A. Yacoub, P. Gupta, M. A. Park, M. Rhamani, H. Hamed, D. Hanna, G. Zhang, D. Sarkar, I. V. Lebedeva, L. Emdad, et al.
Regulation of GST-MDA-7 toxicity in human glioblastoma cells by ERBB1, ERK1/2, PI3K, and JNK1-3 pathway signaling
Mol. Cancer Ther., February 1, 2008; 7(2): 314 - 329.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
L. Emdad, I. V. Lebedeva, Z.-Z. Su, D. Sarkar, P. Dent, D. T. Curiel, and P. B. Fisher
Melanoma differentiation associated gene-7/interleukin-24 reverses multidrug resistance in human colorectal cancer cells
Mol. Cancer Ther., November 1, 2007; 6(11): 2985 - 2994.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
P. B. Fisher
Is mda-7/IL-24 a "Magic Bullet" for Cancer?
Cancer Res., November 15, 2005; 65(22): 10128 - 10138.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
Y. Oida, B. Gopalan, R. Miyahara, S. Inoue, C. D. Branch, A. M. Mhashilkar, E. Lin, B. N. Bekele, J. A. Roth, S. Chada, et al.
Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer
Mol. Cancer Ther., February 1, 2005; 4(2): 291 - 304.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.